Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-ranging study of MVT-602 during controlled ovarian stimulation
NL-OMON46304Phase 2Completed
- Sponsor
- Myovant Sciences
- Start
- May 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TAK-448 in female infertility and anovulation (3 arms), sponsored by Myovant Sciences. Primary endpoint: Exposure-response relationship of MVT-602 on luteinizing hormone concentrations. Started May 2018; status: completed.
02
Drugs
TAK-448
03
Conditions
female infertilityanovulation
Beyond the preview
Go deeper on NL-OMON46304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46304.